Stock Analiz

TELA Bio, Inc. TELA

Medical/Dental Instruments · IPO 2019 · data as of November 13, 2026

$0.82Market cap $37M
Open the interactive analysis →

TELA Bio, Inc. (TELA) is a healthcare company listed in the US with a market value of about $37M. In the twelve months to September 30, 2026 it had revenue of $78M and net income of -$42M, a net margin of -53.6%.

Its overall Stock Analiz score is 1.2 out of 5 (weak). The strongest part is future growth (4/5); the weakest is value (0/5).

Key numbers: 5-year revenue growth of 35% a year, a 5-year average ROIC of -49%.

About TELA Bio

TELA Bio is listed in the US and classified in medical/dental instruments, IPO year 2019. Revenue went from $4M in 2017 to $80M in 2025, growth of about 44.4% a year. It was profitable in 0 of the last 9 years in our data. Its share count rose by 189% over three years (dilution for shareholders). It spends 11% of revenue on research and development.

Score: 1.2 / 5

Value0/5
Future growth4/5
Track record1/5
Financial health0/5
Shareholder returns1/5

Checks passed

  • Revenue growth above 10% last year
  • 3-year revenue growth above 10% a year
  • Profit margin improving
  • Strong R&D investment or growth above 20%
  • 5-year revenue growth above 8% a year
  • Stock-based pay below 5% of revenue

Checks not passed

  • P/E below 25
  • P/E below the industry median
  • P/FCF below 20
  • Price below intrinsic value (DCF, moderate assumptions)
  • PEG below 1.5
  • 3-year free cash flow growth above 10% a year
  • 5-year EPS growth above 10% a year
  • 5-year average ROIC above 12%

Valuation

P/E (TTM)—
Forward P/E—
P/FCF—
P/S0.5
P/B—
EV/EBITDA—
PEG—
Dividend yield0.00%
FCF yield-92.8%
Shareholder yield0.0%
Intrinsic value vs. price—

Growth and quality

Revenue growth (1 yr)15.8%
Revenue growth (5 yrs, per year)34.5%
EPS growth (5 yrs, per year)—
FCF growth (3 yrs, per year)—
Net margin (5-yr avg.)-80.5%
ROIC (5-yr avg.)-49.2%
Profitable years (of last 10)0
Years paying a dividend—

Financials, last 9 years

Fiscal yearTTM202520242023202220212020201920182017
Revenue$78M$80M$69M$58M$41M$29M$18M$15M$8M$4M
Net income-$42M-$39M-$38M-$47M-$44M-$33M-$29M-$22M-$21M-$21M
Free cash flow-$34M-$29M-$43M-$41M-$42M-$31M-$25M-$26M-$20M-$16M
EPS (diluted)$-0.74$-0.83$-1.33$-2.04$-2.72$-2.30$-2.23$-17.10$-101.41$-73.07
Net margin-53.6%-48.4%-54.6%-79.8%-106.9%-112.9%-158.1%-145.2%-254.9%-502.6%
ROIC—-41.7%-47.5%-56.5%-55.2%-45.1%-25.0%-24.7%——

From the company’s 10-K and 10-Q filings with the SEC. TTM = trailing twelve months.

Frequently asked questions

Does TELA Bio pay a dividend?

Not currently.

Is TELA Bio a good stock to buy?

We do not give buy or sell advice. TELA Bio scores 1.2 out of 5 on our five checks (value, growth, track record, financial health and shareholder returns); the checks above show why.

Similar companies

Generated from SEC filings, analyst consensus estimates and market prices, rebuilt every day. Educational information, not investment advice.